AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|
19.2 C
New York
Friday, November 6, 2026

Tag: business

Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030

"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON,...

VALLOUREC FINALISE LA CESSION DE SERIMAX

VALLOUREC FINALISE LA CESSION DE SERIMAX

Bar Partners Modernizes Bar Entertainment Nationwide with Verizon Connectivity

Introducing a zero-cost, fully connected entertainment model driving revenue growth for bars and venues nationwide AUSTIN, Texas, July 23, 2025 /PRNewswire/ -- Bar Partners, North America's...

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Allspring Closed-End Funds Declare Monthly Distributions and Announce a Portfolio Manager Change

CHARLOTTE, N.C., July 25, 2025 /PRNewswire/ -- The Allspring Income Opportunities Fund (NYSE American: EAD), the Allspring Multi-Sector Income Fund (NYSE American: ERC), and...

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to...

ATLANTA, July 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

STL reports Q1 FY26 results; continued positive momentum in Revenue and Order Book

YoY growth in Revenue and EBITDA of ~17% and ~94%, respectivelyOrder intake of INR 1,500+ Cr in Q1 FY26MUMBAI, India, July 25, 2025 /PRNewswire/...

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

Vonage Receives Recognition from Gartner® for Communications Platform as a Service: Named a Customers’ Choice and a Visionary

Customers worldwide recommend Vonage's Communications Platform as a Service (CPaaS), receiving a Gartner Customers' Choice recognition; company recognized as a Visionary in the Gartner...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBusiness